5884-22-0

Basic information

• Product Name: 1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride
• Synonyms: 1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride;DIHYDROALKALI HYDROCHLORIDE;1-[(3,4-diMethoxyphenyl)Methyl]-6,7-diMethoxy-3,4-dihydroisoquinoline hydrochloride;LRUSBWIBSILYNE-UHFFFAOYSA-N
• CAS NO: 5884-22-0
• Molecular Formula: C₂₀H₂₃NO₄*ClH
• Molecular Weight: 377.86186
• EINECS: 227-560-0
• Mol File: 5884-22-0.mol
• Article Data: 10

Chemical Properties

• Melting Point: 202℃
• Boiling Point: 482.6°Cat760mmHg
• Flash Point: 196.9°C
• Appearance: /
• Density: g/cm³
• Vapor Pressure: 5.28E-09mmHg at 25°C
• Refractive Index: 1.554
• CAS DataBase Reference: 1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride(5884-22-0)
• EPA Substance Registry System: 1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride(5884-22-0)

Safety Data

• Hazardous Substances Data: 5884-22-0(Hazardous Substances Data)

Usage

General Description

1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride is a chemical compound with a complex structure that contains a benzyl and isoquinolinium moiety. It is a quaternary ammonium salt that has multiple methoxy groups attached to the benzyl and isoquinolinium rings. 1-(3,4-dimethoxybenzyl)-3,4-dihydro-6,7-dimethoxyisoquinolinium chloride is used in chemical research and pharmaceutical development due to its potential biological activity, particularly as an antiarrhythmic agent. It has been studied for its effects on cardiac ion channels and its potential use in treating heart rhythm disorders. Additionally, this compound may have applications in the development of new drugs for various medical conditions.

InChI:InChI=1/C20H23NO4/c1-22-17-6-5-13(10-18(17)23-2)9-16-15-12-20(25-4)19(24-3)11-14(15)7-8-21-16/h5-6,10-12H,7-9H2,1-4H3

Upstream product

• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 102011-15-4 N-<2-(3,4-dimethoxyphenyl)ethyl>-3,4-dimethoxyphenylacetamide 
• 139-76-4 N-(3,4-dimethoxyphenethyl)-2-(3,4-dimethoxyphenyl)acetamide 

Downstream Products

• 1354039-86-3 (R)-2-[(S)-(1-3,4-dimethoxybenzyl)-6,7-dimethoxy-3,4-dihydro-1H-isoquinolin-2-yl]-N-isopropyl-2-phenylacetamide 
• 54417-52-6 (S)-1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-1,2,3.4-tetrahydroisoquinoline hydrochloride 
• 522-57-6 papaveraldine 
• 1075726-79-2 (1R)-1-[(3,4-dimethoxyphenyl)-methyl]-1,2,3,4-tetrahydro-6,7-dimethoxy-2-benzyloxycarbonylethyl-isoquinoline oxalate 
• 50896-90-7 (-) N-norlaudanosine 
• 64228-81-5 cisatracurium besylate 
• 64228-84-8 N,N'-4,10-dioxa-3,11-dioxotridecylene-1,13-diyl-bis-(R)-(-)-tetrahydropapaverine 
• 181423-71-2 14-(3,4-dimethoxyphenyl)-2,3,11,12-tetramethoxy-8,9-dihydro-6H-chromeno[4',3':4,5]pyrrolo[2,1-a]isoquinolin-6-one 
• 6429-04-5 1,2,3,4-tetrahydro-1-(3,4-dimethoxybenzyl)-6,7-dimethoxyisoquinoline hydrochloride 
• 61-25-6 papaverine hydrochloride 

Relevant articles and documents

Preparation of powder injection pharmaceutical composition from high-purity papaverine hydrochloride

The invention relates to preparation of a powder injection pharmaceutical composition from high-purity papaverine hydrochloride, in particular to a preparation method of papaverine hydrochloride. Themethod comprises the following steps of: heating 3, 4-dimethoxy-beta-phenyl-ethylamine and 3, 4-dimethoxy-phenyl-acetic acid to melting, and then carrying out reaction in a mixture of benzene and chlorethoxyfos to obtain 6, 7, 3', 4'-tetramethoxy-1-benzyl-dihydro-isoquinoline hydrochloride; then dissolving the wet product in tetrahydronaphthalene after the wet product becomes free alkali, and carrying out dehydrogenation reaction at 180DEG C in the presence of a Raney nickel catalyst; after dehydrogenation is finished, directly filtering the tetrahydronaphthalene reaction mixture from the Raney nickel catalyst into a mixture of a hydrochloric acid aqueous solution and methanol; filtering out precipitates, and performing recrystallizing from the ethanol-water solution in an inert gas environment to obtain off-white 6, 7, 3', 4'-tetramethoxy-1-benzyl isoquinoline hydrochloride, namely papaverine hydrochloride. The invention also relates to a papaverine hydrochloride powder injection pharmaceutical composition, and a preparation method and a quality detection method thereof. The invention achieves excellent technical effects as described in the specification.

Application of differential reactivity towards synthesis of lamellarin and 8-oxoprotoberberine derivatives: Study of photochemical properties of aryl-substituted benzofuran-8-oxoprotoberberines

A unique differential reactivity between dihydroisoquinolines and 3-nitrocoumarins was observed and was exploited for the efficient construction of lamellarins and their isomeric benzofuran-8-oxoprotoberberine derivatives under acid-catalyzed or base-promoted conditions. Further, these prepared aryl-substituted benzofuran-8-oxoprotoberberine derivatives bearing electron-donating substituents on benzofuran moiety are found to be benchtop stable but light-sensitive, and can undergo oxidative ring-opening reaction to give the corresponding keto products when exposed to visible light under aerobic conditions.

Discovery and Characterization of ACT-335827, an Orally Available, Brain Penetrant Orexin Receptor Type1 Selective Antagonist

Stress relief: Orexin neuropeptides regulate arousal and stress processing through orexin receptor type1 (OXR-1) and 2 (OXR-2) signaling. A selective OXR-1 antagonist, represented by a phenylglycine-amide substituted tetrahydropapaverine derivative (ACT-335827), is described that is orally available, penetrates the brain, and decreases fear, compulsive behaviors and autonomic stress reactions in rats. Copyright